Regenxbio to resubmit Hunter syndrome gene therapy without new studynews2026-06-22T11:14:56+00:00June 22nd, 2026|Endpoints News|
Definium reports Phase 3 hit for LSD drug in severe form of depressionnews2026-06-22T11:06:58+00:00June 22nd, 2026|Endpoints News|
AbbVie makes $10.9B move for Apogee’s long-acting I&I drug candidatesnews2026-06-22T11:03:23+00:00June 22nd, 2026|Endpoints News|
A Sanofi alum looks to take on the TL1A field with $165M for Bionyranews2026-06-22T11:00:47+00:00June 22nd, 2026|Endpoints News|
Sanofi R&D leader Houman Ashrafian to depart, Paulo Fontoura to take the reinsnews2026-06-22T10:50:34+00:00June 22nd, 2026|Endpoints News|
Nura Bio gets $73.8M to advance SARM1 inhibitors for neurodegenerationnews2026-06-22T10:00:08+00:00June 22nd, 2026|Endpoints News|
